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The Interaction between Methionine Sulfoxide Reductase A and Csn5/Jab1 
 
ABSTRACT 
Oxidative stress can cause toxic outcomes to cells/organisms’ survival. To counter this 
toxicity, multiple cellular mechanisms were evolved. Among them is the methionine sulfoxide 
reductase (Msr) system. Methionine sulfoxide reductase A (MsrA) plays a key role in protecting 
cells from oxidative stress. In our previous studies we discovered a novel role of MsrA in the 
regulation of ubiquitin (Ub) and Ub-like modification of proteins. To further understand the role 
of MsrA in posttranslational modification of proteins, a yeast-2-hybrid (Y2H) screening was 
performed to screen for potential substrates for MsrA in brain. Accordingly, one of the major 
identified substrates was a protein denoted as COP9 signalosome subunit 5 (CSN5, also known 
as Jab1 or COPS5), containing a unique binding site to MsrA. The COP9 signalosome complex 
(CSN) is an essential regulator of the ubiquitin conjugation pathway by mediating the removal of 
Nedd8, an Ub-like protein modifier, from proteins (deneddylation process). Importantly, the 
Csn5/Jab1 contains a domain that provides the catalytic center of the CSN complex. The known 
substrates for neddylation and deneddylation (by CSN) are the cullin subunits and their 
homologues (e.g. Cul-1 of the SCF-type E3 ligase complexes). Furthermore, we showed that 
MsrA interacts with Csn5/Jab1 in mouse brain following immunoprecipitations and pull-down 
experiments. This interaction was compromised in brain extracts of MsrA knockout (MsrA KO) 
compared with the parent wild type (WT) brains. A decrease in the levels of neddylated Cul-1 
was also observed in liver extract of MsrA KO mouse, while the levels of Csn5/Jab1 in brain 
were the same in both the WT and MsrA KO strains. These data suggested that MsrA positively 
regulates Csn5/Jab1 deneddylation activity, presumably via reduction of this protein MetO 
residue/s. To further study the relationship between neddylation level and MsrA in vivo, we used 
yeast strains with various expression levels of MsrA. These yeast strains were WT, MsrA KO and 
MsrA overexpressed (OE) yeast strains. Neddylation levels of yeast under the condition of 
hydrogen peroxide or human Csn5/Jab1 inhibitor were investigated. The data showed that both 
oxidative stress and Csn5/Jab1 inhibitor caused inhibition of deneddylation activity of Csn5/Jab1 
in the absence of MsrA, while MsrA-containing strains (i.e. WT and OE) showed a strong ability 
to protect against H2O2/Csn5/Jab1 inhibitor induced neddylation. For in vitro assays, we used 
artificial Nedd8 conjugates monitoring deneddylation activity in extracts of brains of WT and 
MsrA KO mice strains as function of incubation time. The acquired data showed that the 
deneddylation activity was dramatically reduced in the MsrA KO compared with the WT brain 
extracts. In conclusion, the presented data provide direct and indirect evidence to support our 
hypothesis that MsrA plays an important role in maintaining the Csn5/Jab1 deneddylation 
activity. Lastly, we investigated the potential role of MsrA in regulating of neddylation levels in 
brain cancer. Glioblastoma is one of the most aggressive brain cancers. This cancer type 
demonstrates a relative low level of neddylation compared with normal brain cells. Accordingly, 
Csn5/Jab1 could be one of the posttranslational regulated proteins that may contribute to this 
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phenomenon. We have indeed found that the neddylation level was reduced in glioblastoma cells, 
while the level of Csn5/Jab1 was unchanged compared with normal brain cells. This observation 
pointed to the possible role of MsrA in enhancing Csn5/Jab1 activity in these cancer cells. This 
possibility will be further investigated by comparing the MsrA activities in both the normal and 
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LIST OF ABBREVIATIONS 
COP9: Constitutive photomorphogenic-9 signalosome 
CRL: Cullin-RING ubiquitin ligase 
CSN: COP9 signalosome 
CSN5: COP9 signalosome subunit 5 
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MsrA: Methionine Sulfoxide Reductase A 
NAE: Nedd8 activating enzyme 
NCE: Nedd8 conjugating enzyme 
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CHAPTER 1: INTRODUCTION 
1.1 The Methionine Sulfoxide Reductase System and MsrA 
1.1.1 The Methionine Sulfoxide Reductase System 
Methionine (Met) is an essential amino acid for most mammals, including humans. It is also 
one in addition to cysteine (Cys) that is a sulfur-containing amino acid. Methionine has an S-
methyl thioester side chain, which is easily to oxidize to methionine sulfoxide (MetO). Oxidized 
Met residues in proteins can be frequently found in biological samples. These oxidized proteins 
usually exhibit impaired activity. For example, phosphoglucomutase, chymotrypsin1 and the 
pituitary adrenocorticotropin2 are inhibited as the consequence of methionine oxidation. 
Remarkably, serum protein α1-proteinase inhibitor (α1-antitrypsin) is inactivated due to a critical 
Met residue oxidation3. 
Oxidative stress is usually driven by environmental and cellular factors. It is manifested by 
the production of reactive oxygen species (ROS) that in turn can be toxic to the organism. ROS 
are often generated as a byproduct of cell metabolism4. Apoptotic mechanisms and exogenous 
substances such as chemotherapy drugs could also contribute to ROS generation5.  
To counter the threat of oxidative stress, multiple antioxidant systems have evolved, among 
them is the methionine sulfoxide reductase (Msr) system. This system is highly conserved 
through evolution and can be found in mammals as well as in bacteria and archaea6. This system 
is also the only one that can specifically reduce oxidized protein-bound and free methionine. The 
Msr system consists of two types of enzymes, MsrA and MsrB that reduce methionine sulfoxide 
in its S and R form, respectively. In most organisms there is one type of MsrA and three types of 
MsrB (MsrB1/2/3). MsrA is a positive regulator of MsrB expression7. In most of biological 
systems, Msr system utilize reduced thioredoxin as the natural reducing agent. In vitro activity 
assays suggest that the Msr system can use various cellular reduction powers to reduce MetO. 
For example, reduced forms of either thioredoxin, glutathione, or Dithiothreitol (DTT) can serve 
as reduction powers for the Msr activity. Through the cycled reduction of MetO to Methionine, 
the Msr system can scavenge ROS and then alleviate oxidative stress in organisms8. 
1.1.2 Methionine Sulfoxide Reductase A 
Methionine sulfoxide reductase A was initially identified in studies on the reactivation of 
oxidized Escherichia coli ribosomal protein L129. It is a highly conserved protein and MsrA 
gene family also shows high homology among different species10. The mammalian MsrA was 
first sequenced by Dr. Moskovitz and was found to be 64% identically homologues to the 
bacterial form11. This observation suggest that the MsrA has an important evolutionary role in 
most organisms. The in vivo reducing ability of MsrA is tightly associated with 
Thioredoxin/NADPH system. Thioredoxin (Tx) receives an electron from NADPH and by that it 
is converts to its reduced form. Reduced Tx is the natural electron donor for reducing the Cys 
2 
 
residues of MsrA allowing MsrA to reduce MetO. The reduction of MetO proceeds through 
nucleophilic attack of the catalytic Cys on the sulfoxide with concomitant protonation of the 
oxygen. The regeneration of the reductase activity passes through formation of a disulfide bond 
in the MsrA enzyme, which possess a recycling Cys12,13. Recent studies have reported that a 
subtype of MsrA (which have two recycling Cys) could have a stereospecific oxidase activity in 
conditions where reducing power is absent14.  
MetO-containing proteins/peptides, as well as free MetO can serve as substrates for MsrA in 
vivo and in vitro. Synthetic substrates for MsrA can facilitate in vitro evaluation of MsrA activity. 
For example, 4-dimethylaminoazobenzene-4'-sulfonyl-L-methionine-dl-sulfoxide (DABS-L-
MetO) can be reduced by MsrA in vitro with the presence of DTT and the product of the reaction 
can be separated by chromatography using HPLC-C18 column and accordingly the MsrA 
activity can be quantified15. 
Mammalian MsrA is expressed throughout the body, while the highest expression levels are 
commonly detected in liver and kidney, followed by brain16.   
1.1.3 The role of MsrA in disease 
The absence of MsrA could lead to various cellular malfunctions. The disruption of msrA 
gene in Saccharomyces cerevisiae was shown to cause hypersensitivity of the mutated yeast 
strain to oxidative stress compared to wild-type strain17. Likewise, the MsrA KO mouse is more 
vulnerable to oxidative stress and demonstrates several molecular phenotypes that can be linked 
to age-associated diseases18. For example, some characterized phenotypes are associated with 
Alzheimer’s disease (AD)19 and Parkinson’s Disease (PD)20. Lack of MsrA can cause other 
organ or cellular malfunctions that are not directly linked to neurodegeneration. For example, 
mental health disorders21,22, heart disease23, liver toxicity24 and cancer25. Additionally, MsrA is 
involved in maintaining the basic cochlea structure, in which its deficiency may contribute to 
hearing loss26. In conclusion, MsrA seems to be involved and regulate many cellular processes 
that affect the integrity and function of the whole organism, a specific organ, or cellular 
development as function of age and oxidative stress conditions.   
1.2 COP9 Signalosome Subunit 5 and neddylation 
1.2.1 Csn5/Jab1 
Csn5, also known as COPS5 or Jab1, is the fifth subunit of the constitutive 
photomorphogenic-9 signalosome (COP9). It was initially identified as c-Jun activation domain-
binding protein-1 (Jab1)27.The COP9 signalosome (CSN) is an evolutionary conserved among all 
eukaryotes, multi-subunit complex with a canonical composition of eight subunits (Csn1–8) 
found in all multicellular organisms. CSN regulates the activity of the largest family of ubiquitin 
E3 ligases, Cullin-RING ubiquitin ligases (CRLs). Regulation of CRLs by the CSN involves the 
catalytic activity of Nedd8 hydrolysis from the cullin scaffold subunit of CRLs through a 
metalloprotease MPN+/JAMM motif within the catalytic subunit, Csn5/Jab1. In short, CSN 
promotes deneddylation of Cullin (i.e. Cul-1) and Csn5/Jab1 provide the catalytic center to fulfil 
this function28,29.  
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Csn5/Jab1 contains a c-Jun binding domain (JBD), an Mpr1-Pad1-N-terminal (MPN) 
domain containing the Zn2+-metalloprotease motif (JAMM) that provides the catalytic center to 
the complex for the CSN isopeptidase activity30,31. Interestingly, although Csn5/Jab1 only 
exhibits deneddylase activity when it interacts with the other CSN components32,33, a large 
portion of the free Csn5/Jab1 is detected in both cytoplasm and nucleus34, while CSN-associated 
Csn5/Jab1 is mainly in present in the nucleus. The Csn5/Jab1 mediated deneddylation of Cul-1 
act as an upstream regulator of SCF-dependent ubiquitination of numerous substrates, including 
p27 and IκBα35. 
Recently, researches have suggested that Csn5/Jab1 is overexpressed in cancer36. While 
Csn5/Jab1 is systemically expressed in both tumor tissues and normal tissues, Csn5/Jab1 
expression levels in cancers are significantly higher than those in normal tissues. Csn5/Jab1 
overexpression was reported in many types of cancers, including hepatocellular carcinoma 
(HCC)37, pancreatic cancer38, breast cancer39, non-small cell lung cancer (NSCLC)40, 
nasopharyngeal carcinoma (NPC)41, and many others42. 
1.1.2 Neddylation 
Neddylation is a posttranslational modification that adds ubiquitin-like protein that is termed 
as neural precursor cell expressed developmentally down-regulated 8 (Nedd8) to substrate 
proteins43. As a member of Ubiquitin-like molecule (UBL), Nedd8 covalently conjugated to a 
limited number of cellular proteins in a manner analogous to ubiquitination. In a canonical 
neddylation process, Nedd8 is activated by Nedd8 Activating Enzyme (NAE)44. Nedd8 is then 
transferred from the NAE via the Nedd8 conjugating enzyme (NCE) and the RING-box protein 
RBX1 to the Cullin subunit of Cullin-RING E3 ubiquitin ligases (CRL)45. RBX1 serves as the 
E3 ligase for Nedd8 and as an E3 ligase for subsequent ubiquitination reactions46. The Cullin 
subunits of CRLs are the best-studied neddylation substrates. CRLs are stabilized by RBX1-
mediated Cullin neddylation at their conserved WHB domain. Neddylation loosens the 
interaction of RBX1 with the WHB domain and RBX1 can subsequently promote E2-dependent 
ubiquitination and protein degradation47. CRLs are the largest family of multiunit E3 ubiquitin 
ligases, controlling degradation of about 20% of proteasome-regulated proteins, involving in 
many aspects of important biological processes48,49,50. Over-activation of CRLs leads to cancer 
growth and development51. Nedd8 and enzymes of neddylation pathways are often 
overexpressed in multiple human cancers, which are associated with cancer progression and poor 
patient prognosis52. Over-activated neddylation pathway also leads to the elevated global 
neddylation of substrates, to consequently promote degradation of tumor suppressor (e.g. p21 
and p27) and facilitate oncogenesis and tumor progression. Thus, regulating neddylation 
pathways can be a potential anticancer strategy.  
1.3 Glioblastoma 
Glioblastoma is the most common and most aggressive primary malignant brain tumor in 
adults53. It comprises 15% of all intracranial neoplasms and 60-75% of astrocytic tumors54. The 
initial signs of glioblastoma are usually non-specific, which include headaches, personality 
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changes, nausea, and symptoms similar to those of a stroke55. Glioblastoma is derived 
specifically from unregulated grown astrocytes, or precursor stem cells that have mutations. The 
mutations can usually be one or a combination of the following: loss of chromosome 10q, 
epithelial growth factor receptor (EGFR) amplification, murine double minute 2 (MDM2) 
overexpression, phosphate and tensin homologue (PTEN) gene mutation, or TP53 mutation56.  
It is very hard to treat glioblastoma. Researchers must face a dilemma of either using 
therapeutic doses of anticancer agents to enable them to enter the blood brain barrier at 
therapeutic concentrations or to avoid them due to their tendency to increase the risk of systemic 
toxicity57. As a result, surgery is considered the first stage of glioblastoma treatment. 
Radiotherapy is also frequently used for the treatment. Chemotherapy has few effects on 
glioblastoma, but Temozolomide (TMZ) is used together with radiotherapy to increase median 
survival time of the patients. Other drugs, i.e. EGFR blocker cetuximab did not go beyond phase 
II trial due to limited effects58. Unfortunately, the median survival time of glioblastoma patients 
following diagnose is still no more than 1 year. Glioblastoma also usually recurs despite 
maximum treatment and the survival is typically 3 months without treatment59. Recent studies60 
showed that Csn5/Jab1 is overexpressed in glioblastoma. We think that our study that unveils 
interaction between MsrA and Csn5/Jab1 may contribute to the knowledge regarding the 
development and progression of glioblastoma and help in establishing a novel MsrA-Csn5/Jab1 -
based glioblastoma treatment. 
1.4 Statement of hypothesis 
We hypothesize that MsrA interacts with Csn5/Jab1 and that this interaction positively 
regulates Csn5/Jab1 function through a reduction of specific MetO residue/s of Csn5/Jab1 that is 




Figure 1. A schematic illustration of the involvement of MsrA in regulating Cul-1 
deneddylation under oxidative stress conditions. The presence of external or internal cellular 
oxidative stress may lead to the formation of reactive oxygen species (ROS) that in turn cause 
oxidation of Met residue/s of Csn5/Jab1, the core subunit of COP9 Signalosome (CSN). 
Deneddylation activity of Csn5/Jab1 is inhibited due to the oxidation. As a result, the substrate of 
Csn5/Jab1, Cul-1 is more neddylated. The presence of MsrA reduces MetO to Met. Thus, it leads 
to an increase of Csn5/Jab1 deneddylation activity. Enhanced deneddylation activity of Jab1 is 




CHAPTER 2: MATERIALS AND METHODS 
2.1 MsrA interacts with Csn5/Jab1 in brain 
2.1.1 Yeast-two-Hybrid Assay Screening for substrates of MsrA  
The yeast two-hybrid (Y2H) screen was performed using a full-length MsrA cDNA 
sequence as bait and an adult human brain cDNA library as the prey [Clontech, product number 
630486: 8 Caucasian males ages 43-66 sudden death, 3.2 x 106 independent clones] was 
performed by the “Next Interactions Inc.” company (Richmond CA).  
The Y2H procedures were performed similarly to Clontech’s protocol of the Matchmaker 
Gold Yeast Two-Hybrid System. Constructs were made using Clontech’s pGBKT7 and pGADT7 
plasmids that are components of the Matchmaker Gold Yeast Two-Hybrid System. The MsrA 
clone was purchased from DNASU Plasmid Repository (https://dnasu.org/DNASU/About.jsp). 
Constructs encoding the MsrA protein in pGBKT7 (“bait”, Trp1 selection marker of Y2HGold 
yeast strain) and pGADT7 (“prey”, Leu2 selection marker, Y187 yeast strain) were mated using 
the following procedure. An YPD-agar plate was used to streak the S. cerevisiae strains and then 
they were incubated in YPD media overnight at 30ºC with rotation at 225 rpm. The S. 
cerevisiae/YPD culture was diluted 1:10 with fresh YPD media and incubated for additional 2 
hours at 30ºC with rotation at 225 rpm (cell density between 107 and 3.0 x107 cells per ml). The 
cells were centrifuged at 580 x g, and the pelleted cells were re-suspended in YPD media and 
plated onto agar plates containing standard selective media (synthetic dextrose;SD) lacking 
tryptophan (Trp) and leucine (Leu) and incubated further for five days at 30ºC. Then, colonies 
from each plate were re-suspended in an Eppendorf tube containing 500 µl of dH2O; and 5 µl of 
this solution spotted onto agar plates lacking Trp and Leu or agar plates containing selective 
media lacking Trp, Leu and histidine (His). Selection for positive clones was done for HIS3 
reporter activation (low stringency, SD-Leu, -Trp, and –His (LTH)) and for HIS3 and ADE2 
reporter activation (high stringency, SD-Leu, -Trp, -His, and -Adenine (LTHA)). An initial 
selection for 5 days was performed. The equivalent of 1.07 x 106 diploid cells was selected on 
SD-LTH and the equivalent of 7.4 x 106 SD-LTHA. We picked the colonies and grew them again 
for 2-3 day on high stringency medium (SD-LTHA) to ensure robust growth. Fifty-three colonies 
were finally obtained and prey cDNAs were amplified with colony PCR using a set of flanking 
primers. The resulting PCR products were then sequenced in the forward direction as follows. 
Colonies from SD-LTH and SD-LTHA agarose plates were picked into a grid to grow larger. 
After re-growth, pipet tips were used to transfer each colony into a 30 μL 20 mM NaOH 
suspension, then boiled for 20 minutes at 99°C in an MJ thermocycler with a hot lid. After 
cooling, lysates were clarified by centrifugation at >3000 x g for 5 minutes. The supernatants 
were amplified by PCR with 1 X Mango Polymerase buffer, 10mM NTPs, 10 μM primers 
NIXO_1838 (5’-gatGAAGATACCCCACCAAACC-3’) and NIXO_1839 (5’-
cacgatgcacagttgaAGTGAA-3’) plus MgCl2 with 0.25 μL Mango Tag DNA polymerase (Bioline) 
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and 0.05 μL HiFi Tag DNA polymerase (Clontech) in a 50 μL reaction mixture. DNA was 
amplified with the following protocol: 95°C for 5 minutes, 10 cycles of 95°C for 30 seconds, 
68°C for 30 seconds, and 72°C for 3 minutes with the annealing temperature lowered by 1°C per 
cycle. The reaction was performed for an additional 30 cycles at 95°C for 30 seconds, 58°C for 
30 seconds and 72°C for 3 min. The reaction had a final extension of 72°C for 5 minutes and was 
held at 12°C until the performance of the analysis. 10 μL from each sample were analyzed by gel 
electrophoresis on a 1% agarose gel in 1X TAE buffer at 115V. The remaining 40 μL were 
sequenced.  
2.1.2 Animal models and brain extracts 
 The mouse model used in the following experiments were C57 Bl6/129Sv MsrA knockout 
/wild-type mouse (MsrA KO/WT) inbreeded for more than 20 generations. The age of the mouse 
used for making brain extracts were 6 months. For consistency propose, only female mice were 
used. The brain extracts (n=3, Female, 6 month) were made by homogenization of post mortem 
brains in phosphate buffered saline (PBS) in the presence of proteases inhibitor cocktail (Cat# 
P8215-1ML, Sigma, St. Louis, MO, USA) and MG132 proteasome inhibitor (Cat# BML-P1102-
0005, Enzo) on ice. The insoluble fraction of each extract was separated by high-speed 
centrifugation (10000 rpm, 10 minutes, 4℃) and then discarded. The supernatants were then 
collected, and their protein concentration was measured. Bradford protein assay was performed 
to measure total protein concentration of the extracts. The optical density was read at 595 nm 
with an iMark microplate reader (BIO-RAD, USA). The protein concentration was then 
calculated. 
2.1.3 GST pull down assay 
 The fused mammalian Sepharose-bound glutathione-S-transferase (GST)-MsrA protein was 
used as the “bate” in the GST pull down assay. Brain extracts of WT and MsrA KO mice were 
made as previously described. The MsrA KO supernatant was incubated with the Sepharose 
GST-MsrA resin or with Sepharose-GST only, serving as control (20 µg protein). The incubation 
was carried out for 2 hours at room temperature followed by overnight incubation at 4ºC. 
Thereafter, the resins were rinsed with PBS by multiple low speed centrifugations (1000 rpm, 
room temperature) until no protein was detected in the washing buffer (PBS). The bound proteins 
moiety of the washed resins was eluted by 2x SDS-gel- electrophoresis buffer (Novex, Carlsbad, 
CA, USA) and separated by 4-20% SDS-gel-electrophoresis (Cat# XP04200BOX, Invitrogen, 
Waltham, MA, USA). Anti-Jab1 antibody (MA1-23248, Invitrogen, Waltham, MA, USA) was 
used as primary antibody in the western blot.  
2.1.4 Immunoprecipitation experiments 
 WT and MsrA KO mouse brain extracts were first incubated with anti MsrA antibody 
(Proteintech Group) (1:100 dilution) for 2 hours on a Glas-Col Rugged Rotator (Cat#099A 
RD4512 Glas-Col, USA) at room temperature. Protein-G Sepharose (GE Healthcare) was 
washed with PBS for 3 times to fully remove the solvent. Then, WT and MsrA KO mouse brain 
extracts and anti MsrA antibody mixture were incubated in the presence of protein-G Sepharose 
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overnight at 4ºC. Thereafter, the resins were washed with PBS by multiple low speed 
centrifugations (1000 rpm, room temperature) until no protein was detected in the washing buffer 
(PBS). The bound proteins moiety of the washed resins was eluted by 2x SDS-gel-
electrophoresis buffer (Novex, Carlsbad, CA, USA) and subjected to western blot analysis. 
2.1.5 Western Blot 
  All western blots in this study were performed using the following protocol: 
The Novex WedgeWell 4-20% Tris-Glycine Gel (Cat#: XP04200BOX, Invitrogen, Waltham, 
MA, USA) was used to separate proteins. Blue Protein Standard (Cat#: P7706S, BioLabs, 
Ipswich, MA, USA) was used to show molecular weight of protein bands. The electrophoresis 
was performed under the condition of 150 V, 76 mA for 70 minutes (Power Supply EC250-90, 
Thermo-Fisher Scientific, Waltham, MA, USA) in the presence of 500 mL 1X Tris-Glycine SDS 
running buffer (LC2675, Novex, Carlsbad, CA, USA). Then the gel was transferred to a 
nitrocellulose membrane (0.45 μm pore size, LC2001, Novex, Carlsbad, CA, USA) in the 
presence of 1000 mL Tris-Glycine transfer buffer (Prod # 28380, Thermo-Fisher Scientific, 
Waltham, MA, USA). Thereafter, the transferred nitrocellulose membrane was incubated with 
5% (w/v) bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA) for one hour. After three 
washes with PBST (0.5% Tween 20 in PBS), the membrane was incubated with anti-MsrA 
antibody (Cat #: 14547-1-AP, Proteintech Group, Rosemont, IL, USA) for 1 hour, followed by 
another three PBST washes and 1 hour incubation with a secondary antibody (Goat anti-rabbit 
IgG (H+L)-HRP Conjugate, Cat #: 170-6515, Bio-Rad, Hercules, CA, USA). Finally, the 
membrane was incubated with ECL detection reagent (Cat#: UC279142 ECL Western Blotting 
Substrate, Pierce). and exposed to an X-ray film. The obtained signals produced by the films 
were scanned using NIH Image-J program. After the ECL incubation, the nitrocellulose 
membrane was also washed and subjected to Ponceau S solution (0.1 % (w/v) in 5% acetic acid 
Ponceau S solution) (Cat#: P3504-10G, Sigma-Aldrich, St. Louis, MO, USA) to show total 
protein levels of each loaded lane of the gel. 
2.2 MsrA promotes Csn5/Jab1 deneddylation activity in vivo  
Wild-type (WT) and MsrA KO (MT) mouse brain and liver extracts (n=3 for each group, 
Female, 6 month) were obtained as previously described. IP experiments were performed in 
which the anti-Cul-1 antibody (Cat#: NB100-2616, Novus Biologicals, Centennial, CO, USA) 
served as the IP antibody and the anti-Nedd8 (Cat#: 0001812M4796, Boster Biological 
Technology, Pleasanton, CA, USA) served as the primary antibody in the followed western blot 
analysis and vise-versa. Another IP experiment in which the anti-Jab1 antibody served as IP 
antibody was performed. This IP experiment was followed by a western blot using anti-Cul-1 
antibody (Cat#: NB100-2616, Novus Biologicals, Centennial, CO, USA) as primary antibody. 
Furthermore, the extracts were also subjected to western blot using Csn5/Jab1 as primary 
antibody. The protocols of IP and WB were the same as described in section 2.1.4 and 2.1.5.  
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2.3 MsrA regulates yeast Rub1 modification levels in yeast 
 Three types of yeast strains (Saccharomyces cerevisiae, wild-type (WT), msrA null mutant 
(MT) and MsrA overexpressed (OE)) were made according to our previous studies61,62. These 
strains were grown separately in conical flasks in the presence of synthetic minimal media in an 
incubator shaker at 30°C (C24 Incubator Shaker, New Burnswick Scientific, Edison, NJ, USA). 
The yeast strains were divided into three groups, while each group consisted of three yeast trains 
(WT, MT, OE). The first group served as the control group and was grown in the synthetic 
minimal media only. The second group was exposed to 2 mM of hydrogen peroxide that was 
added to the medium. The third group was exposed to 1 µM CSN5-i3 (A novel selective human 
CSN5-i3/Jab1 inhibitor that binds to the catalytic site of the JAMM domain63. Kindly provided 
by Novartis) that was added into the media. All groups were incubated with 150 µg/mL 
ampicillin at 30°C for 24 hours. At mid-logarithmic phase, the cells were spun down by 
centrifugation and washed three times with PBS. Then, the cells were resuspended in PBS in the 
presence of yeast protease inhibitors cocktail (Cat #: P8215- 1ML, Sigma-Aldrich, St. Louis, 
MO, USA) and MG132 proteasome inhibitor (Cat#: BML-P1102-0005, Enzo, NY, USA), and 
then extracted by using a glass bead-beater homogenizer apparatus (BioSpec Products, 
Bartlesville, OK, USA). Following high-speed centrifugation, the resulting supernatants were 
collected. The protein concentration of each supernatant was determined by Bradford protein 
assay (Bio-Rad Protein Assay Dye, Cat#: 5000006, Bio-Rad, Hercules, CA, USA). Equal 
amounts of protein extracts were subjected to Western blot analysis using rabbit anti-Rub1 (a 
Nedd8 homologue in yeast) as the primary antibody (Cat#: GTX48823, GeneTex Inc, Irvine, CA, 
USA). Anti-rabbit IgG (Goat anti-rabbit IgG (H+L)-HRP Conjugate (Cat #: 170-6515, Bio-Rad, 
Hercules, CA, USA) was used as the secondary antibody. The western blot protocol was the 
same as described in section 2.1.5. The same nitrocellulose membrane was then subjected to a 
protein staining (Ponceau S), serving as loading control. The major observed bands were scanned 
and quantified using the Image J program. The rubylation (neddylation in yeast) level was 
evaluated by the calculated total strength of Rub1-positive bands. 
2.4 MsrA alters the kinetics of Csn5/Jab1 deneddylation activity in vitro 
2.4.1 Nedd8 conjugates  
Dr. Julie A. Maupin and her co-workers from University of Florida kindly designed a 
heterologous expression model of Flag-His6 tagged Nedd8 in Haloferax volcanii. The Nedd8 
conjugates from Haloferax volcanii was purified and then could be utilized in the following in 
vitro deneddylation assays. The method is described as follows: 
2.4.1.1 Design of system for heterologous expression of Nedd8 in Haloferax volcanii 
An N-terminal tandem Flag-His6- tag was added to the coding sequence for the mature 
Nedd8 protein (Uniprot accession P29595, residues 1-76) with removal of the original initiator 
methionine. The recombinant coding sequence was codon optimized for translation in Haloferax 
volcanii using the Codon Optimization On-Line (COOL) web platform64. NdeI/BlpI restriction 
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sites were added and the entire sequence was synthesized by GenScript (Piscataway, NJ) and 
ligated in pUC57 to create pJAM3518. Flag-His6-Nedd8 was removed from pJAM3518 by 
NdeI/BlpI digest, gel extracted, and ligated in pJAM202 to create pJAM3519. pJAM3519 was 
transformed to E. coli TOP10, and isolated transformants were patched on LB supplemented 
with ampicillin. PCR screening by primers HvFW/RV confirmed presence of the plasmid and 
correct size of the Flag-His6-Nedd8 insert. Several patches were selected, and integrity of the 
insert sequence was verified by Sanger sequencing. pJAM3519 was then passaged through a 
methylation deficient strain of E. coli (GM2163) prior to transformation to H. volcanii.  
2.4.1.2 Purification of Nedd8 conjugates from Haloferax volcanii 
Note – several strains of H. volcanii expressing FHN8 were tested for conjugate formation at 
small scale, HM1096 produced the highest levels observed.  
H. volcanii HM1096 cells expressing pJAM3519 were inoculated at an initial OD of 0.005 
in 4 x 700 mL ATCC974 medium supplemented with 50 mM DMSO and 0.2 ug/mL novobiocin. 
Flasks (2.8L, Fernbach) were incubated at 42°C with 200 rpm orbital shaking for 93 hours. 
Cultures (4) were pooled and centrifuged at 4,000 x g for 15 minutes, gently resuspended and 
washed in TBS-2M (2M NaCl, 50 mM Tris-Cl, pH 7.4). The cells were centrifuged again, the 
supernatant was discarded, and the wet cell pellet (6.28 g) was stored at -80°C until future use. 
After thawing, the cell pellet was resuspended in 35 mL TBS-2M supplemented with protease 
inhibitor cocktail (Thermo Scientific, Cat#:A32955) according to the manufacturer, 5 µg/mL 
DNase I, 2 mM MgCl2, 0.5 mM CaCl2, and incubated on ice for 15 minutes. The suspension was 
passed through a French pressure cell at 20,000 psi five times, supplemented with imidazole at a 
final concentration of 30 mM, and clarified by centrifugation (13,000 x g, 4°C, 20 min). 
Clarified supernatant was filtered through a PES membrane (0.45 µm) and applied to a 1 mL 
HisTrap HP column equilibrated in TBS-2M supplemented with 30 mM imidazole. After loading 
of the lysate, the column was washed in the same buffer until the A280 trace stabilized, then 
eluted using TBS-2M supplemented with 500 mM imidazole. All column chromatography steps 
were performed at a flow rate of 0.5 ml/min. Peak fractions were immediately supplemented 
with 1 mM EDTA and analyzed by reducing SDS-PAGE (12% acrylamide) and subsequent 
Coomassie blue staining and western blotting. Selected fractions (2 mL) were pooled and 
dialyzed at 4°C in TBS-2M with three buffer exchanges over a period of 72 h. The dialyzed 
sample was quantified by BCA assay at a concentration of 1.3 mg/mL, divided into 100 µL 
aliquots, snap freeze, and stored at -80°C until future use.    
2.4.2 In vitro deneddylation activity assay 
Equal amounts of brain extracted protein of WT and MsrA KO mouse were incubated with 
Nedd8 conjugates at 37°C. After designated time of incubation, equal volumes of 2X sample 
buffer were added and immediately heated at 100°C for 5 minutes to terminate the reaction. The 
reaction solution of different time points were then subjected to western blot using mouse anti-
His antibody (Cat#:34610, Qiagen, Venlo, Netherlands) that was used as primary antibody. The 
western blot protocol was the same as described in section 2.1.5. The deneddylation level was 
evaluated by the signal strength of lowest molecular mass His-detected positive band.   
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2.5 Change in Neddylation levels of Cul-1 in glioblastoma postmortem human brains 
We have obtained post-mortem human brain specimens (n=3) from the University of Kansas 
Cancer Center. We isolated tissue sections from the malignant portion of the brains that 
contained glioblastoma tumors, as well as non-tumor sections from adjacent regions that serve as 
controls (basic information of the subjects is given in Table 2). The corresponding tissues were 
extracted in PBS in the presence of protease inhibitors cocktail (Cat #: P8215- 1ML, Sigma-
Aldrich, St. Louis, MO, USA). Following high-speed centrifugation, the supernatants were kept 
and used for the relevant Western blot analyses. IP experiments were performed to determine the 
deneddylation activity of Csn5/Jab1 activity towards Cul-1 in these supernatants. For these IP 
experiments we used the anti-Nedd8 antibody to precipitate neddylated proteins, followed by 
western blot analysis that specifically probed for neddylated Cul-1 by using mouse anti-Cul-1 





CHAPTER 3: RESULTS 
3.1 MsrA interacts with Csn5/Jab1 in brain 
 The result of BlastX screening was analyzed and the following positive clones were 
identified (Table 1). Most prominent prey hits are COP9 signalosome complex subunit 5 (n=19), 
cyclin-I [Homo sapiens] and succinate dehydrogenase [ubiquinone] iron-sulfur subunit [Homo 
sapiens] are 6 copies each. These strong hits were recurring, i.e. more than once. This showed 
that we had specific selection and not just random activation. In addition, 6 more hits were 
unique, i.e. only one copy. The high number of hits obtained for COPS5 (also known as 
Csn5/Jab1) and the involvement of both MsrA and Csn5/Jab1 in the Ub/Ub-like systems, 
prompted us to focus on this MsrA interacting target first.  
We then performed Y2H screening to find out the binding site of MsrA and Csn5/Jab1. We 
first investigated and characterized the specific region of interaction between MsrA and Jab1 by 
using the MsrA as the “bait” and “Csn5/Jab1” as the prey in the Y2H system. Accordingly, we 
used the MsrA clone from the initial Y2H screening and produced a “prey” library consistent of 
various Csn5/Jab1 sequences that were sub-cloned into the “prey” vector. The clone for Jab1 was 
purchased from DANSU Company and its sequence was cut into small fragments that were then 
sub-cloned into the corresponding “prey” vector (the details for this procedure are proprietary 
information of “Next Interactions” Inc., Richmond, CA). The first Y2H screening for identifying 
regions of interaction between MsrA and Jab1 coding segments showed a unique peak of Jab1 at 
the 5' half that indicates binding; the initial peak was relatively broad, when the mapping was 
conducted with 600 bp fragments. However, further mapping experiments yielded a sharper peak 
with a distinct plateau that defines the essential binding site. As shown in Figure 2 below, the 
initial screening defined an in-frame sequence of Jab1 (Positions 93-457 of the open reading 
frame) following a “Sanger” sequence analysis (the underlined sequence). This sequence consists 
of 7.3% Met residues that is higher than the average Met percentile in proteins (~2%). Further 
deeper analysis revealed a sharper peak consistent of 6 pairs of Met including Val residues that 
were aligned as (the percent of Met in this rose to 12.2%) (Figure 2, highlighted in yellow). 
MVM; VMGLM, and MIIM. 
To further confirm the interaction between MsrA and Csn5/Jab1, we then used MsrA 
knockout (MsrA KO) mouse brain extracts to perform a GST pull down assay. Since there was 
no endogenous MsrA in MsrA KO mouse brain extracts, all proteins which interact with MsrA 
would be pulled down by GST-MsrA. In Figure 3A, one lane containing the GST-MsrA protein 
was stained for protein with Coomassie Blue to observe the intensity of the major GST-MsrA 
protein band and the other minor bound proteins. The western blot result indicated that only the 
lane harboring the GST-MsrA showed a signal corresponding to Csn5/Jab1, while the lane 
harboring GST alone showed no reaction as expected. 
In Figure 3B, immunoprecipitation (IP) experiments were performed to further demonstrate 
the MsrA-Csn5/Jab1 interaction. IP experiments using mouse brain extracts with anti-MsrA 
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antibody (IP antibody), followed by western blot analysis using a mouse anti-Jab1 antibody as 
the primary antibody. The results showed that only the lane harboring the GST-MsrA showed a 
signal corresponding to Csn5/Jab1 (a band with molecular weight of ~36 kDa), while the lane 
harboring GST alone showed no positive reaction. This result was consistent with our previous 
Y2H screening result, suggesting an interaction between Csn5/Jab1 and MsrA. The antibody 
used as the western blot primary antibody was a mouse generated anti-Jab1 antibody. Therefore, 
in addition to the detected Csn5/Jab1 protein in the WT mouse extracts (and not in the MsrA KO 
mice), two additional reactions with the mouse immunoglobulin light (L) and heavy (H) chains 
were observed. These results suggested that there was an interaction between Csn5/Jab1 and 
MsrA in mouse brain.    
3.2 MsrA promotes Csn5/Jab1 deneddylation activity in vivo 
 We then focused on investigating the possibility that MsrA would activate Csn5/Jab1 
function. We followed the in vivo deneddylation activity of Csn5/Jab1 on its substrate Cullin-1 
(Cul-1) as function of the presence or absence of MsrA in mouse brain and liver extracts. As 
mentioned above, MsrA is also highly expressed in liver tissues. The use of liver extracts was 
also followed to show that the effect of MsrA on Csn5/Jab1 function is general in nature.  
 IP experiments in which the anti-Cul-1 antibody served as the IP antibody and the anti-
Nedd8served as the primary antibody in the followed western blot analysis (and vise-versa) were 
performed to test our hypotheses. As shown in Figure 4A a & b, compared to WT brain, MsrA 
KO brain showed higher level of neddylated Cul-1. Higher Cul-1 neddylation level was also 
observed in MsrA KO liver extracts compared to WT (Figure 4A c & d). Higher neddylation 
levels of Cul-1 in the MsrA KO brain and liver suggested an impaired deneddylation activity in 
the absence of MsrA. This phenomenon was also in agreement with our hypothesis that 
reduction of specific MetO residue/s of Csn5/Jab1 lead to increase of its activity, as measured by 
deneddylation of Cul-1. In the absence of MsrA (i.e.as it is in the MsrA KO tissue extracts) the 
activity of Csn5/Jab1 was compromised presumably due to its enhanced Met oxidation, resulting 
in more neddylation (or less deneddylation) of Cul-1. Furthermore, an active Csn5/Jab1 was 
supposed to bind to Nedd8 moiety of Cul-1 in before removing it from Cul1 (or any other target 
protein). Therefore, anti-Csn5/Jab1 antibody could also be used in an IP experiment as a 
“fishing” probe to isolate protein complexes of neddylated Cul-1 that is bound to Csn5/Jab1 from 
biological extracts (prior to the removal of Nedd8 by Csn5/Jab1 and its associated cofactors). 
Indeed, following this approach, the WT brain showed much higher neddylated Cul-1 than the 
MsrA KO (MT), as judged by western blot analysis using anti Cul-1 antibody followed by the IP 
with anti-Jab1 antibody (Figure 4A e). These data confirmed that Csn5/Jab1 was able to bind 
Nedd8 on Cul-1 more effectively in the presence of MsrA, supporting the hypothesis stated 
above. We then performed another western blot analysis to investigate whether Csn5/Jab1 levels 
changed in MsrA KO compared with the WT mouse brain extracts. The results showed that the 
presence/absence of MsrA had no effect on the level of Csn5/Jab1 (Figure 4 D). This 
observation indirectly supports our hypothesis, that MsrA regulates Csn5/Jab1 deneddylation 
activity through post-translational protein modification and not through changing 
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Csn5/Jab1expression levels.  
3.3 MsrA regulates yeast Rub1 modification levels in yeast  
  To investigate the in vivo regulation of deneddylation in a whole living organism/cells and 
determine the effect of oxidative stress and Csn5/Jab1 inhibition, we used yeast cells.  
Related to Ubiquitin-1 (Rub1) is the yeast homolog of Nedd8. Orthologues of Nedd8/Rub1 
are required for vitality in all studied organisms. However, budding yeast (Saccharomyces 
cerevisiae) is a notable exception. In S. cerevisiae, neither CSN nor Rub1 are essential for 
viability65. Nevertheless, the CSN complex drives canonical cullin derubylation, yet it is unclear 
for what mechanistic purpose66,67. Thus S. cerevisiae is a proper model for our studies. Like in 
mammalians, the substrate of yeast Csn5/Jab1 is Cdc53-Rub1 (Cullin-Nedd8 in mammals). To 
investigate whether the Rub1 post-translational modification is Csn5/Jab1 dependent, we used a 
selective human Csn5/Jab1 inhibitor CSN5-i3 provided by Novartis. We tested the Rub1 
modification levels of wild type (WT), MsrA Knockout (MT) and MsrA overexpressed (OE) 
yeast trains in oxidative stress (H2O2) or in the presence of CSN5-i3, respectively. The yeast 
extracts were obtained via methods described above. The Rub1 modification levels of the yeast 
strains grown under different conditions was monitored via western blot analysis, as shown in 
Figure 5. 
 Accordingly, the total rubbylation levels were determined following western blot analysis 
using anti-Rub1 antibody as the primary antibody (Figure 5A) and quantified (Figure 5B). An 
increase of rubbylation level was observed in WT yeast strain in the presence of H2O2 (t-test, 
p<0.05) while a decrease in the level was observed in CSN5-i3 group compared to control (t-test, 
p<0.05) (upper panel). These data suggest that oxidative stress inhibits total deneddylase activity 
that probably includes also the activity of Csn5/Jab1. However, CSN5-i3 did not show inhibitory 
effect on Csn5/Jab1 activity, likely due to its decreased affinity towards the yeast homologue of 
the human Csn5/Jab1. The MsrA KO yeast demonstrated a significant increase of rubbylation 
level under conditions of both H2O2 and Csn5/Jab1 inhibitor treated groups, compared to control 
(t-test p<0.001) (middle panel). The fact that the CSN5-i3 showed a better inhibitory effect when 
MsrA is absent suggests that CSN5-i3 may have a higher affinity to a more Met-oxidized state of 
the yeast form of Csn5/Jab1. In MsrA OE yeast, neddylation levels significantly decreased in 
H2O2 and Csn5/Jab1 inhibitor treated groups (t-test, p<0.05). This phenomenon can be explained 
by the overexpression of MsrA that can better scavenge the ROS formed by H2O2. 
Environmental oxidative stress could also stimulate MsrA promoter to increase MsrA levels in 
yeast, and especially in the OE strain, leading to further increase of Csn5/Jab1 activity. The 
failure of CSN5-i3 to inhibit rubylation in the MsrA OE strain could also be due to the low 
affinity of the inhibitor to non-oxidized Csn5/Jab1, which is even better protected from oxidation 
in the OE strain. 
3.4 MsrA alters the kinetics of brain Csn5/Jab1 deneddylation activity in vitro. 
 As we hypothesized, MsrA may regulate Csn5/Jab1 activity by reducing MetO residues of 
the protein. That is to say, different oxidation levels of Csn5/Jab1 may show different catalytic 
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kinetics. Thus, we focused on the kinetics of the Csn5/Jab1 deneddylation reaction in vitro by co-
incubating artificial Csn5/Jab1 substrate, Nedd8 conjugates with WT and MsrA KO mouse brain 
extracts. High amount of His-tagged Nedd8 conjugates (6 µg) were used to get as closely as 
possible to the effective Km value to be able to follow the kinetics deneddylation activity (while 
not overloading the Nedd8 protein per gel lane) in WT and MsrA KO brain extracts. Anti-His 
antibody was used to detect the Nedd8 signal due to its high selectivity compared with the anti-
FLAG antibody that seems to have non-specific reactions with mouse brain proteins (data not 
shown). The levels of the lowest molecular weight Nedd8 (L.M.Nedd8) was monitored to 
evaluate total deneddylation levels. The results showed that the deneddylation levels of WT and 
KO groups remained the same at zero time of incubation (T0)(Figure 6A&B). However, the 
MsrA KO group exhibited much lower levels of released low-molecular weight Nedd8 compared 
to the WT as the incubation time increased. The deneddylation level of WT strain rapidly 
reached the peak after10 minutes of incubation that was much higher than the same peak 
observed for the MsrA KO strain (Figure 6B). This big difference in the deneddylation activity 
between the two strains remained up to the end of the incubation time (30 minutes). Accordingly, 
it is suggested that the MsrA KO brain exhibits much more Met-oxidized Csn5/Jab1 protein 
compared with the WT brain. This phenomenon is in agreement with our hypothesis that lack of 
MsrA compromises the deneddylation activity of Csn5/Jab1 through an increase of Csn5/Jab1 
MetO levels  
3.5 Change in Neddylation levels of Cul-1 in postmortem glioblastoma human brains 
 As shown in Table 2, we obtained post-mortem human brain specimens (n=3) from the 
University of Kansas Cancer Center. We isolated tissue sections from the malignant portion of 
the brains that contained glioblastoma tumors, as well as non-tumor sections from adjacent 
regions that serve as controls. IP experiments were performed to determine the deneddylation 
activity of Jab1 activity towards Cul-1 in brain supernatants. For these IP experiments an anti-
Nedd8 antibody was used to precipitate neddylated proteins, followed by western blot analysis to 
specifically probe for neddylated Cul-1 by using anti-Cul-1 antibody, as the primary antibody. As 
shown in Figure 7A&B, the levels of neddylated of Cul-1 were higher in the control groups 
compared to the malignant tumor samples following the IP-Western blot analyses. The data 
suggest that the deneddylation activity of Csn5/Jab1 was higher in the neuroblastoma tumor 
cells, as expected from its higher expression levels68. Interestingly, we did not observe any 
significant difference between the Csn5/Jab1 levels in tumor and control tissues (Figure 7D). 
One possible explanation is that the number of samples we have is small and there may be 
differences between the subjects in each study that influence the data. In any event, the lack of 
Csn5/Jab1 expression differences between the control and malignant groups supports the 
suggestion that indeed posttranslational modification plays a role in the observed deneddylation 
differences of Cul-1. 
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CHAPTER 4: CONCLUSION AND DISCUSSION 
 The interaction between Csn5/Jab1 and MsrA was confirmed via different methods in this 
study. An Y2H assay was first used to screen the potential binding proteins of MsrA. Further 
analysis unveiled several potential binding sites between MsrA and Csn5/Jab1 (Figure 2). Then 
we focused on confirming this binding in vivo. An MsrA KO mouse model was used to find out 
whether the interaction between MsrA and Csn5/Jab1 happens naturally in animals. The GST 
pull down data suggest that there is an interaction between MsrA and Csn5/Jab1 in mouse brain 
(Figure 3). Immunoprecipitations experiments showed that absence of MsrA causes decreased 
deneddylation level of Cul-1 in brain (Figure 4A a & b). MsrA KO Cul-1 showed approximately 
3 times more neddylation compared to WT (Figure 4B). We also found that the same interaction 
between two proteins exists in liver of mouse, another highly expressed MsrA organ (Figure 4A 
c & d). These data suggest that the MsrA-dependent deneddylation activity (most likely carried 
out by Csn5/Jab1) is a common feature in several organs. Interestingly, Csn5/Jab1 level remained 
the same in MsrA KO mouse brain compared to WT (Figure 4D). This result is in agreement 
with our hypothesis that MsrA regulates Csn5/Jab1 deneddylation activity via a mechanism of 
posttranslational modification instead of directly elevating the expression levels of this protein. 
In Figure 5, we discovered that deneddylation was inhibited by oxidative stress in both WT and 
msrA KO yeast strains. However, overexpression of MsrA fully restored oxidative stress induced 
inhibition of deneddylation. Interestingly, the Csn5/Jab1 inhibitor CSN5-i3 can only inhibit 
deneddylation activity in msrA KO yeast. We suggested that oxidation levels of Csn5/Jab1 could 
change its affinity to the inhibitor. These results were consistent with our hypothesis that 
deneddylation activity of Csn5/Jab1 is MsrA dependent. As a proteolytic enzyme, the 
deneddylation activity of Csn5/Jab1 is supposed to be altered by MsrA catalyzed MetO residues 
reduction. As we observed in Figure 6, the deneddylase kinetics of Csn5/Jab1 was altered in the 
absence of MsrA. Decreased activity of MsrA KO extract to deneddylate artificial Nedd8 
conjugate suggest a correlation between the reductase activity of MsrA and Csn5/Jab1 activity. 
More studies are required to further confirm whether impaired Csn5/Jab1 activity is directly due 
to the oxidation of Met to MetO in the absence of MsrA. IP and western blot analysis in post 
mortem human glioblastoma brain tissues showed an increased Csn5/Jab1 activity in tumor 
samples compared to control, while total Csn5/Jab1 protein levels remained the same (Figure 7). 
Determination of an increase of MsrA activity in glioblastoma cells compared to controls will 
provide further supportive evidence for the positive role of MsrA in enhancing Csn5/Jab1 








CHAPTER 5: FUTURE DIRECTION 
 Proteins are known to exhibit changed activities under different levels of oxidation. Aging69 
or environmental factor-driven oxidative stress may lead to abnormal protein function or even 
diseases. As a crucial antioxidant enzyme, MsrA plays a key role in maintaining the balance of 
oxidation-reduction in organisms. Given that MetO was observed in a various of proteins in 
normal physiological conditions, it is not surprising that MsrA could also regulate the activity of 
the substrate protein by decreasing protein oxidation levels, in this case, reducing MetO to Met. 
A few proteins were found out to alter activity due to increased MetO residues. For example, 
Alpha-antitrypsin is a serine protease inhibitor (serpin) which has surface exposed Mets. 
Oxidation of Met351 and Met358 in the protein causes a loss of the antineutrophil elastase 
activity associated with emphysema. Addition of MsrA in vitro can partly restore the antielastase 
activity70. In our study, the results clearly showed a positive regulatory role of MsrA to the 
deneddylation activity of Csn5/Jab1 both in vivo and in vitro. Considering the main reductase 
function of MsrA, we hypothesized that MsrA upregulates Csn5/Jab1 activity via a mechanism 
of reducing MetO residues to Met on Csn5/Jab1 protein. Under natural conditions, a moderate 
level of oxidative stress is present that makes a portion of Met residues on Csn5/Jab1 oxidized to 
MetO. This represents the basal level of Csn5/Jab1 activity. Under high oxidative stress 
conditions, more Met residues are supposed to be oxidized to MetO, leading to inhibition of 
Csn5/Jab1 deneddylation activity. Under MsrA overexpressed conditions, almost all S-MetO 
residues are supposed to be reduced to Met, leading to a higher Csn5/Jab1 deneddylation activity 
than detected in the basal level. Accordingly, the role of MsrA is supposed to maintain the 
hemostasis of Csn5/Jab1 deneddylation activity  
 To further confirm this hypothesis, the following experiments will help to illustrate the 
mechanism of MsrA mediated Csn5/Jab1 activity increase. 
1. MsrA activity assay. To fully understand the role of MsrA in glioblastoma, we plan to 
investigate MsrA activity in tumor tissues. Using DABS-L-MetO as the substrate, the 
activity in tumor tissues could be quantified by measuring MsrA specific activity. Then 
we could evaluate the interaction between Csn5/Jab1 deneddylation activity and the 
activity of MsrA and determine the role of MsrA in neddylation-related disease 
development. According to our hypothesis, we expect to observe an increased MsrA 
activity in tumor tissues. 
2. GST-Csn5/Jab1 Pull Down Assay. To further confirm the interaction between MsrA and 
Csn5/Jab1, a GST Pull Down assay using GST-Csn5/Jab1 as bait can be performed 
following the same IP protocol described in section 2.1.3. We expect that the assay result 
will also show an MsrA-Csn5/Jab1 interaction 
3. Mutagenesis of Csn5/Jab1 Met residues. To fully uncover the binding situation of MsrA-
Csn5/Jab1, performing mutagenesis of Csn5/Jab1 Met residues is necessary. According to 
our preliminary data we have obtained in Y2H screening, the Jab1 binding site to MsrA 
was identified. Within the 70 amino acids of the brain Csn5/Jab1 binding site there were 
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three sets of adjacent Met and Val residues as follows:  
5’-MVMHARSGGNLEVMGLMLGKVDGETMIIM‐3’.  
We plan to mutate individually each highlighted Met and Val residue to Ala to reduce 
hydrophobicity. Thus, initially we will create eight individual mutants of either Val or 
Met, followed by eight double and eight triple mutants of the Met/Val residues per patch 
(a grand total of 24 mutants). It is expected that at least one of the mutated patches will 
reduce the binding of Jab1 to MsrA following the Y2H screening. If no difference in 
binding will be observed, we will create two additional mutants in which two and all 
three patches will be fully mutated. For performing the mutagenesis, we will use and 
follow the protocol provided by the manufacture of the Quick-change site directed 
mutagenesis kit (Agilent Technologies). 
4. Mass Spectrum Analysis of Csn5/Jab1 oxidation levels/sites. It is important to determine 
the actual Met oxidation level of Csn5/Jab1, as well as their sequence location sites in the 
presence and absence of MsrA. Thus, we plan to improve our yeast model and analyze 
the MetO levels of recombinantly expressed Csn5/Jab1. We will overexpress human and 
yeast recombinant His-tagged Csn5/Jab1 in MsrA null mutant and WT yeast strains, 
respectively. Then, we will grow the cells in expression synthetic media in the presence 
or absence of H2O2 or CSN5-i3. Thereafter, each recombinant Csn5/Jab1 will be affinity 
purifies from each strain and the relative MetO levels and sequence location will be 
determined by mass-spectrometry analyses. We predict that the oxidative stress will 
increase the levels of MetO residue/s of either Csn5/Jab1 form, especially in the MsrA 
null mutant strain. Moreover, it is predicted that the CSN5-i3 will inhibit better the 
deneddylation activity of the human -recombinant Csn5/Jab1 than the yeast- recombinant 





















Table 1. Count of Hit BlastX results 
Hits Protein name Species 
1 AT-rich interactive domain-containing protein 2 Homo sapiens 
1 coatomer subunit beta' Homo sapiens 
19 COP9 signalosome complex subunit 5 Homo sapiens 
6 cyclin-I Homo sapiens 
1 heat shock 70 kDa protein 4L Homo sapiens 
1 phenylalanyl-tRNA synthetase beta chain Homo sapiens 
1 protein FAM184A isoform 2 Homo sapiens 
6 
succinate dehydrogenase [ubiquinone] iron-sulfur subunit, 
mitochondrial precursor 
Homo sapiens 
























Table 2. Postmortem human brain tissues 
Specimen Tissue review Gender Race Ethnicity Diagnosis 
Malignant frozen 







WHO Grade IV 
Adjacent 
nonmalignant tissue 









































-The tissues are listed in pairs of CB and MB that originated from the same individual (CB is the 























Figure 2. Protein sequence of Jab1 region that binds MsrA. Analysis of the interaction 
between MsrA and Jab1 using the Y2H system revealed an MsrA-interaction domain in Jab1 
protein sequence (underlined). This interaction domain has a peak (highlighted in yellow), 
containing patches of a Met and Val mixtures sequences that are closely positioned (in bold, 






















Figure 3. Interaction between MsrA and Jab1 in mouse brain extracts.  
A. Pull-down experiments in which recombinant GST-MsrA fused protein is used as a “bait” for 
binding of brain proteins. MsrA KO brain extracts were used in the pull-down assay. Coomassie 
Blue staining showed GST-MsrA positive band (left). Jab1 was detected in the lane harboring 
GST-MsrA (right, lane 2). B. IP experiments using mouse brain extracts with anti-MsrA (IP 
antibody), followed by western blot analysis using a mouse anti-Jab1 as the primary antibody. 
kDa, molecular mass markers in kilo-Dalton units; WT, wild-type mouse; MT, MsrA KO mouse; 
L, light chain of mouse immunoglobin detected in the extract; H, heavy chain of mouse 
immunoglobulin detected in the extract. This experiment was repeated 3 times and one set of 

















Figure 4. Regulation of Jab1 activity by MsrA in vivo through monitoring Cul-1 
neddylation levels in mouse brain and liver extracts. A. a-d. (Mice age, 6 months, n=3). 
Immunoprecipitation (IP) experiments were performed on brain and liver extracts (500µg of 
protein per extract) using either anti-Cul-1 antibody or anti-Nedd8 followed by western blot 
analyses using anti-Nedd8 or anti-Cul-1 antibody as the primary antibody, respectively. e. anti-
Jab1 antibody was used as a“fishing” probe in an IP experiment using brain extracts, followed by 
western blot analysis with anti-Cul-1. B. Quantification of the neddylated band of Cul-1 by 
Image-J program, following the performed western blot analyses. All the differences in 
deneddylation levels between the WT and MT pairs were statistically significant as judged by 
student t-test analysis (P<0.01, n=3 per strain). C. Loading controls for the liver and brain 
protein levels, following Coomassie blue staining. D. Western blot analysis of mouse brain 
extracts using anti-Jab1 antibody as primary antibody. WT, wild type; M, MsrA KO; WB, 
Western blot analysis; Arrows in Aa-e indicate the position of the neddylated 100kDa Cul-1 
(non-neddylated form runs as 90 kDa protein, not detected). WT, wild-type mouse; MT, MsrA 
KO mouse. The shown WB and Coomassie staining experiments are representatives of three 











Figure 5. MsrA regulates yeast Rub1 modification levels in yeast. A. Western blot of three 
different yeast strains (Wild-type, msrA knockout and MsrA overexpress) in three different 
conditions (Control, H2O2 and CSN5-i3) using anti-Rub1 antibody as primary antibody (upper 
panel); total protein staining (Ponceau S) as loading control (lower panel). The shown WB and 
Ponceau S staining experiments are representatives of three repeated experiments. B. 
Quantification of total rubbylation levels. All data are normalized and showed as percentage to 
control, respectively. Student t-test was used to analysis the data. (n=3; *p<0.05; **p<0.001). 





Figure 6. MsrA alters the kinetics of Csn5/Jab1 deneddylation activity in vitro. A. The 
western blot pattern of control group (time 0’). Total protein neddylation levels were shown. We 
focused on lowest molecular weight Nedd8 positive bands as they were the products of 
deneddylation process. B. lowest molecular weight Nedd8 positive bands at different time points 
in WT and MsrA KO mouse brain samples (n=3, female, 6 month). C. Time curve of lowest 
molecular weight Nedd8 levels. All data were normalized to T0. The shown WB are 
representatives of three repeated experiments that showed. WT: Wild-type; KO: MsrA Knockout; 











Figure 7. Neddylation levels of Cul-1 as function of the presence of glioblastoma in 
postmortem human brains. A. For the IP experiments, an anti-Nedd8 antibody was used and 
for the WB analysis, an antiCul-1 was used as the primary antibody. B. Each paired of tissue 
supernatants (Tumor and Control) were separated on SDS gel/electrophoresis and stained with 
Coomassie blue stain to confirm the equal protein amounts used. C. The relative neddylation 
levels of each sample was quantified by densitometry analysis of the Cul-1 band (see panel A), 
using the Image-J program. The difference in the Nedd8 levels between the control and Tumor 
samples was statistically significant as judged by student t-test analysis (n=6, p<0.001). M, 
molecular mass-markers (Bio-labs); C, control tissue; T, Tumor sample; the arrow indicated the 
100 kDa neddylated Cul-1 band. The data in Panels A and B are representative data of the total 
six samples that were analyzed and showed a similar pattern of neddylation with respect to their 
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